Paper10071185
Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency.
Van Kuilenburg AB and 24 others. Hum Genet, 1999. Cited by 216 papers, by iCite.
Cite this record
ConductScience Library. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Papers, record 10071185. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10071185
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Oxidoreductases | Major topic |
| Animals | |
| Dihydrouracil Dehydrogenase (NADP) | |
| Genotype | |
| Humans | |
| Phenotype |
Source PubMed
Cited by78
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 216 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42947977 | Survey-based perspectives and reported barriers to DPYD testing among U.S. oncologists. | Front Oncol | 2026 | https://conductscience.org/library/papers/42947977 | PubMed |
| 41131702 | Functional studies of human variants in C. elegans link iron metabolism to DPD deficiency and 5-FU sensitivity. | Genetics | 2026 | https://conductscience.org/library/papers/41131702 | PubMed |
| 40422899 | Plasma Metabolic Outliers Identified in Estonian Human Knockouts. | Metabolites | 2025 | https://conductscience.org/library/papers/40422899 | PubMed |
| 40238917 | Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity. | Sci Transl Med | 2025 | https://conductscience.org/library/papers/40238917 | PubMed |
| 40217360 | The diagnosis and treatment of disorders of nucleic acid/nucleotide metabolism associated with epilepsy. | Acta Epileptol | 2025 | https://conductscience.org/library/papers/40217360 | PubMed |
| 38895199 | Expansion of a bacterial operon during cancer treatment ameliorates drug toxicity. | bioRxiv | 2024 | https://conductscience.org/library/papers/38895199 | PubMed |
| 38528593 | A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report. | BMC Med Genomics | 2024 | https://conductscience.org/library/papers/38528593 | PubMed |
| 37537644 | BEDwARS: a robust Bayesian approach to bulk gene expression deconvolution with noisy reference signatures. | Genome Biol | 2023 | https://conductscience.org/library/papers/37537644 | PubMed |
| 37256229 | Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37256229 | PubMed |
| 37204596 | A Rare Genetic-Metabolic Cause of Epileptic Spasms: Dihydropyrimidine Dehydrogenase Deficiency. | Indian J Pediatr | 2023 | https://conductscience.org/library/papers/37204596 | PubMed |
| 36848609 | Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine. | JCO Precis Oncol | 2023 | https://conductscience.org/library/papers/36848609 | PubMed |
| 36661700 | DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation. | Curr Oncol | 2023 | https://conductscience.org/library/papers/36661700 | PubMed |
| 36241945 | Identification of fungal dihydrouracil-oxidase genes by expression in Saccharomyces cerevisiae. | Antonie Van Leeuwenhoek | 2022 | https://conductscience.org/library/papers/36241945 | PubMed |
| 35865463 | Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing. | Front Oncol | 2022 | https://conductscience.org/library/papers/35865463 | PubMed |
| 35804978 | Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35804978 | PubMed |
| 35302652 | Modern developments in germline pharmacogenomics for oncology prescribing. | CA Cancer J Clin | 2022 | https://conductscience.org/library/papers/35302652 | PubMed |
| 34653361 | The dihydropyrimidine dehydrogenase gene contributes to heritable differences in sleep in mice. | Curr Biol | 2021 | https://conductscience.org/library/papers/34653361 | PubMed |
| 33805100 | An Evaluation of the Diagnostic Accuracy of a Panel of Variants in DPYD and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related Toxicities. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33805100 | PubMed |
| 33542850 | Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen? | J Adv Pract Oncol | 2020 | https://conductscience.org/library/papers/33542850 | PubMed |
| 33317085 | Development of a Pharmacogenetic Lab-on-Chip Assay Based on the In-Check Technology to Screen for Genetic Variations Associated to Adverse Drug Reactions to Common Chemotherapeutic Agents. | Biosensors (Basel) | 2020 | https://conductscience.org/library/papers/33317085 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| DPYD | 1806 | PubTator's text mining | https://conductscience.org/library/genes/1806 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/10071185
GET https://conductscience.org/api/papers/v1/10071185/authors?page=2